Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00681980
Recruitment Status : Completed
First Posted : May 21, 2008
Last Update Posted : December 3, 2015
Information provided by (Responsible Party):
Jorge Casseb, University of Sao Paulo

Brief Summary:
Is the valproic acid efficacy to treat TSP/HAM

Condition or disease Intervention/treatment Phase
Paraparesis Spastic Tropical Drug: Valproic acid Drug: costicosteroids Drug: valproid acid plus corticosteroids Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil
Study Start Date : February 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: A, 2, III
Patients with side effects to corticosteroids
Drug: Valproic acid
15 mg/kg/day

Experimental: B
patient with corticosteroids
Drug: costicosteroids
metypredsolone 1 g/day

Experimental: 3
Valproic acid and corticosteroids
Drug: valproid acid plus corticosteroids
valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient

Primary Outcome Measures :
  1. Neurological sacles [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Quality of life [ Time Frame: 2009 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HTLV-1; TSP/HAM fulfill criteria

Exclusion Criteria:

  • Age <18 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00681980

Layout table for location information
Institute of Tropical Medicine at Sao Paulo University
Sao Paulo, SP, Brazil, 0543903
Sponsors and Collaborators
University of Sao Paulo

Layout table for additonal information
Responsible Party: Jorge Casseb, Professor, University of Sao Paulo Identifier: NCT00681980    
Other Study ID Numbers: 278
First Posted: May 21, 2008    Key Record Dates
Last Update Posted: December 3, 2015
Last Verified: December 2015
Keywords provided by Jorge Casseb, University of Sao Paulo:
TSP/HAM, HTLV-1, treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Valproic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs